Single nucleotide polymorphisms in XRCC1 and outcome in gastric cancer patients receiving oxaliplatin based chemotherapy

魏嘉,张微,邹征云,钱晓萍,禹立霞,刘宝瑞

DOI: https://doi.org/10.3321/j.issn:1001-0580.2007.07.030

2007-01-01

Abstract:Objective To investigate whether the single nucleotide polymorphism(SNP) in DNA repair gene XRCC1(X-ray repair cross-complementing 1) were associated with the survival of 5-FU/oxaliplatin combination chemotherapy in gastric cancer.Methods Overau survival time of 62 gastric cancer patients receiving platinum-based chemotherapy were investigated.XRCC1 genotypes were assessed using 5′ nuclease allelic discrimination assay(TaqMan) using real-time PCR.Results The median survival time of all 62 gastric patients was 461 days.The median survival time of patients with Arg/Arg or Arg/Gln genotypes was 490 days compared with 295 days of others(P=0.022).Conclusion XRCC1 399 SNP was predictive marker of survival for gastric cancer patients receiving platinum-based chemotherapy.